FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387380030> ?p ?o ?g. }

• W4387380030 abstract "Abstract Disclosure: V. Paakinaho: None. Steroid receptors, such as androgen (AR), and glucocorticoid receptor (GR), are hormone-controlled transcription factors (TFs) that regulate transcription in multiple central cellular systems. The action of steroid receptors has a major role in the development and progression diseases, especially endocrine-related cancers, such as prostate cancer. Since AR is the key oncogenic TF driving the development and progression of prostate cancer, the receptor is the major precision drug target in the disease. Therefore, antiandrogen treatment, i.e., the inhibition of AR activity, is a common form of cancer therapy. Despite the initial effectiveness of the therapy, antiandrogen resistance often occurs and there is no curable treatment in many cases. In contrast to AR, GR has been thought to possess tumor suppressive properties in therapy-naïve prostate cancer. Nonetheless, GR can hijack the oncogenic role of AR in prostate cancer by replacing the antiandrogen inactivated AR thus mediating antiandrogen-resistance and becoming the driver of the disease. Yet, the genome-wide effects of GR in prostate cancer have largely remained elusive. The tumor suppressive versus the oncogenic consequences of GR activation are important to acknowledge since prostate cancer patients regularly receive glucocorticoids to reduce inflammation and alleviate therapy-related side effects. To unveil these issues, we integrated ChIP-seq, RNA-seq, ATAC-seq data and uncover several pivotal features of GR action in prostate cancer cells. We detected that the replacement of AR by GR in antiandrogen-exposed prostate cancer cells occurs almost exclusively at pre-accessible chromatin sites displaying the occupancy of FOXA1. Counterintuitively to the classical pioneer factor model, the silencing of FOXA1 potentiated the chromatin binding and transcriptional activity of GR. This was attributed to FOXA1-mediated repression of the NR3C1 (gene encoding GR) expression via the corepressor TLE3. Additionally, we discovered that the chromatin binding of GR as well as transcriptional regulation by the receptor differs between different prostate cancer subtypes. Moreover, GR activity in normal prostate cells diverges drastically from that of the cancer cells. In sum, our data highlight the impact FOXA1 harbors in GR-mediated antiandrogen-resistant prostate cancer. Furthermore, the distinct GR transcriptional activity in prostate cancer subtypes could potentially be used to determine if glucocorticoid exposure possess potential harm for the prostate cancer patient. Presentation: Saturday, June 17, 2023" @default.
• W4387380030 created "2023-10-06" @default.
• W4387380030 creator A5029206198 @default.
• W4387380030 date "2023-10-01" @default.
• W4387380030 modified "2023-10-16" @default.
• W4387380030 title "OR22-04 The Oncogenic Action Of Glucocorticoid Receptor In Prostate Cancer" @default.
• W4387380030 doi "https://doi.org/10.1210/jendso/bvad114.1765" @default.
• W4387380030 hasPublicationYear "2023" @default.
• W4387380030 type Work @default.
• W4387380030 citedByCount "0" @default.
• W4387380030 crossrefType "journal-article" @default.
• W4387380030 hasAuthorship W4387380030A5029206198 @default.
• W4387380030 hasBestOaLocation W43873800301 @default.
• W4387380030 hasConcept C121608353 @default.
• W4387380030 hasConcept C126322002 @default.
• W4387380030 hasConcept C134018914 @default.
• W4387380030 hasConcept C170493617 @default.
• W4387380030 hasConcept C2776235491 @default.
• W4387380030 hasConcept C2776551883 @default.
• W4387380030 hasConcept C2779322244 @default.
• W4387380030 hasConcept C2780192828 @default.
• W4387380030 hasConcept C502942594 @default.
• W4387380030 hasConcept C59493245 @default.
• W4387380030 hasConcept C61367390 @default.
• W4387380030 hasConcept C71924100 @default.
• W4387380030 hasConceptScore W4387380030C121608353 @default.
• W4387380030 hasConceptScore W4387380030C126322002 @default.
• W4387380030 hasConceptScore W4387380030C134018914 @default.
• W4387380030 hasConceptScore W4387380030C170493617 @default.
• W4387380030 hasConceptScore W4387380030C2776235491 @default.
• W4387380030 hasConceptScore W4387380030C2776551883 @default.
• W4387380030 hasConceptScore W4387380030C2779322244 @default.
• W4387380030 hasConceptScore W4387380030C2780192828 @default.
• W4387380030 hasConceptScore W4387380030C502942594 @default.
• W4387380030 hasConceptScore W4387380030C59493245 @default.
• W4387380030 hasConceptScore W4387380030C61367390 @default.
• W4387380030 hasConceptScore W4387380030C71924100 @default.
• W4387380030 hasIssue "Supplement_1" @default.
• W4387380030 hasLocation W43873800301 @default.
• W4387380030 hasOpenAccess W4387380030 @default.
• W4387380030 hasPrimaryLocation W43873800301 @default.
• W4387380030 hasRelatedWork W2523942339 @default.
• W4387380030 hasRelatedWork W2561061456 @default.
• W4387380030 hasRelatedWork W2737056430 @default.
• W4387380030 hasRelatedWork W2767048879 @default.
• W4387380030 hasRelatedWork W4362495086 @default.
• W4387380030 hasRelatedWork W4362495275 @default.
• W4387380030 hasRelatedWork W4362609250 @default.
• W4387380030 hasRelatedWork W4362609326 @default.
• W4387380030 hasRelatedWork W4362621709 @default.
• W4387380030 hasRelatedWork W4362621793 @default.
• W4387380030 hasVolume "7" @default.
• W4387380030 isParatext "false" @default.
• W4387380030 isRetracted "false" @default.
• W4387380030 workType "article" @default.